PainRelief.com Interview with: Kanu M. Okike, MD Orthopedic Surgeon The Hawaii Permanente Medical Group
PainRelief.com: What is the background for this study? What are the main findings?
Response:Hip corticosteroid injections are a common treatment for osteoarthritis and other hip conditions. Recently, isolated case reports have raised the question of whether hip corticosteroid injections could be associated with rapid progression of the arthritis process – a condition known as rapidly destructive hip disease (RDHD).
PainRelief.com Interview with: Stuart L. Silverman MD FACP FACR Clinical Professor of Medicine, Cedars-Sinai Medical Center and UCLA School of Medicine Medical Director, OMC Clinical Research Center Beverly Hills, CA 90211
Dr. Silverman
PainRelief.com: What is the background for this study?
Response: As a practicing rheumatologist, I am aware that prior studies have shown variation in medical care, pain management and treatment with opioids by race and social economic status. Suboptimal treatment of pain in patients with osteoarthritis (OA) may also disproportionately burden racial minorities and Medicaid recipients.
Studies have shown that African Americans are nearly 1.5 times as likely to have symptomatic knee OA than White patients even when adjusting for other factors. Similarly, they also have a higher prevalence of symptomatic and radiographic hip OA. Analyses of Medicare data has shown evidence of persistent racial disparities for joint arthroplasty usage and surgical outcomes.
PainRelief.com Interview with: Mitsuru Mizuno, DVM, Ph.D. Assistant professor at CSCRM, Principal investigator for this study and Ichiro Sekiya, M.D., Ph.D..
PainRelief.com: What is the background for this study? What are the main findings?How are the stem cells obtained?
Response: We have developed a cell therapy for treating difficult-to-heal meniscus injury using mesenchymal stem cells (MSCs) derived from the synovium of the knee. However, trisomy 7 is often found in synovial cells obtained from patients with osteoarthritis, a disease that occurs with aging.
PainRelief.com Interview with: Dr. Siddharth A. Padia, MD Interventional Radiology Ronald Reagan UCLA Medical Center UCLA Santa Monica Medical Center
Dr. Padia, MD
PainRelief.com: What is the background for this study?
Response: Osteoarthritis (OA) of the knee can be a debilitating condition with significant impact on a person’s overall quality of life. OA has historically been considered a “wear-and-tear” disease, resulting from years of stress induced cartilage degeneration. Recent data suggests that inflammation plays a role not only in the experience of pain secondary to osteoarthritis, but is a driver of OA itself.
Genicular artery embolization (GAE) is a minimally invasive procedure where the arteries supplying the lining of the knee are selectively catheterized during an angiogram to target abnormally increased blood flow associated with knee osteoarthritis. Injection of small, microspheres results in a reduction in arterial flow, which may in turn reduce the synovial inflammation.
PainRelief.com: What are the main findings?
Response: 40 subjects were enrolled in this trial. Technical success was achieved in 100% of subjects. Transient skin discoloration and transient mild post-procedure knee pain were common and expected. Pain scores decreased from a 8 (out of 10) at baseline to 3/10 (63% decrease) at 12 months. Twenty-seven patients (67.5%) had greater than a 50% reduction in pain scores.
PainRelief.com: What should readers take away from your report?
Response: Genicular artery embolization is a highly promising therapy for people with knee arthritis, who are not surgical candidates or which to defer surgery. It is the first non-surgical treatment that has shown to have a significant reduction in pain with a duration of at least one year. It is minimally invasive, and most people can resume their everyday activities the evening after their procedure.
PainRelief.com: What recommendations do you have for future research as a result of this work?
Response: This was a single arm trial, in that genicular artery embolization was not compared to other treatments. Future research needs to show a comparison to other treatments or placebo in order to prove its efficacy. Additionally, long-term result (2 and 4 years) would be beneficial to show the durability of GAE over time.
Citation:
Abstract No. 16 Genicular artery embolization for the treatment of knee osteoarthritis: final results from a prospective investigational device exemption trial Padia, S. et al. Journal of Vascular and Interventional Radiology, Volume 32, Issue 5, S8
The information on PainRelief.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.
PainRelief.com Interview with: Bruce J. Sangeorzan, M.D., Professor Director, RR&D Center for Excellence in Limb Loss Prevention and Prosthetic Engineering Veterans Affairs University of Washington
PainRelief.com: What is the background for this study?
Response: We began a series of studies in the early 2000’s when ankle replacement was limited to a few centers like our own. We knew that ankle arthrodesis– or fusion—was an effective treatment for ankle arthritis. But ankle fusion is not appropriate for some people and it also results in loss of ankle motion. There were a growing number of ankle replacements being done but little was known about their effectiveness or how long they last.
We wanted to study whether replacement and fusion were comparable for pain relief and activity and wanted to know if maintaining motion of the ankle (by using a replacement) would have an advantage without additional risk. Three studies were done involving more than 800 patients from 6 centers.
This most recent study compared two groups of patients who had similar amount of pain and activity before treatment. All of the patients had already tried non -surgical solutions such as activity modification, bracing and injections with out improvement. One group had fusion of the ankle and the other had replacement of the ankle. Patients were questioned and examined four years or more after surgery and compared to their condition before treatment.
PainRelief.com Interview with: Dr Thomas Perry PhD| Postdoctoral Research Fellow Versus Arthritis Centre for Sport, Exercise and Osteoarthritis Research Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences
Dr. Perry
PainRelief.com: What is the background for this study?
Response: Management of knee osteoarthritis (OA) is multi-factorial and routinely involves the use pharmacological interventions; with most medications aimed at alleviating painful symptoms and improving function.
Little is known of the long-term effects of such medications on the structural progression of radiographic knee OA. Through examining the relationship between pharmacological interventions and the disease pathway, this may, in turn, identify potential areas for disease-modifying treatment development.
PainRelief.com Interview with: Xiaoqian Liu Clinical research fellow (Wednesday/Thursday) Rheumatology Department| Royal North Shore Hospital Institute of Bone and Joint Research | Sydney Medical School
PainRelief.com: What is the background for this study?
Response: Hand osteoarthritis (HOA) is a prevalent joint disease, causing symptoms in up to 10% of the general adult population worldwide. Hand pain is the most common symptom in addition to functional disability and decreased quality of life. Due to the modest effects and/or potential harms, current traditional treatment such as exercise, non-inflammatories and analgesics frequently do not meet patients’ demand. More and more people are turning to complementary and alternative medicines for pain relief.
In our previous work, we identified four dietary supplements with promising treatment effects for relieving pain which are Boswellia serrata extract, curcumin, pine bark extract and methylsulfonylmethane (MSM). The hypothesis was that combining these supplements to generate an enhanced benefit for people with HOA. The aim of the RADIANT study was to investigate the efficacy and safety of a 12-week course of this supplement combination in people with painful HOA who were confirmed with the diagnosis on their hand x-ray.
PainRelief.com Interview with: Stephen P. Messier, PhD .B. Snow Biomechanics Laboratory Department of Health and Exercise Science Wake Forest University Winston-Salem, North Carolina
Dr. Messier
PainRelief.com: What is the background for this study? What are the main findings?
Response:Thigh muscle weakness is associated with knee discomfort and osteoarthritis disease progression. Little is known about the efficacy of high-intensity strength training in patients with knee osteoarthritis and whether it may worsen symptoms.
PainRelief.com Interview with: Rebecca L Robinson Patient Outcomes and Real-World Evidence Eli Lilly and Company, Indianapolis, IN
PainRelief.com: What is the background for this study?
Response: Osteoarthritis (OA) pain is unfortunately common and greatly affects patients’ quality of life. Treatment varies from patient to patient and can include nonpharmacologic therapies, over-the-counter (OTC) and prescription pain medications, as well as surgery. The combination of these treatment modalities and especially the use of acetaminophen, NSAIDs or opioids in OA patients has not been examined thoroughly. This study helps to address this gap while also demonstrating variations in treatment received by patients with different levels of pain severity. We analyzed data from the United States OA Adelphi Disease Specific Programme (DSP), which links patient and physician perspectives on the management of OA via cross-sectional surveys.
PainRelief.com Interview with: Felix M. Gonzalez, M.D. Radiology Department at Emory University School of Medicine Atlanta, Georgia
PainRelief.com: What is the background for this study? What are the main findings?
Response: Arthritis afflicts 30 million Americans yearly with the most common form being degenerative arthritis. The main joints affected are the knee, hip and shoulder joints.
Osteoarthritis is exceedingly common, affecting more than 32.5 million Americans, according to the U.S. Centers for Disease Control and Prevention. The condition arises when the cartilage cushioning the joint breaks down over time, leading to pain, stiffness and decreased range of motion. People with osteoarthritis often take over-the-counter painkillers, such as ibuprofen (Advil, Motrin) and naproxen (Aleve). But besides being only moderately effective, the drugs are not without risks: Prolonged use is linked to increased risks of heart disease and kidney damage. Corticosteroid injections, which reduce inflammation, are the next option. But their effectiveness wanes over time and there are long-term safety issues, including a risk of cartilage damage.
Gonzalez and his colleagues treated 23 patients whose hip or shoulder pain had become so bad that anti-inflammatory painkillers and cortisone injections — two standard treatments — were no longer helping.
Before undergoing ablation, and again three months later, patients answered standard questionnaires gauging their pain and daily function.
In the end, the study found, patients with shoulder arthritis reported an 85% drop in their pain ratings, on average. Among hip arthritis patients, pain declined by an average of 70%.
The information on PainRelief.com is provided for educational purposes only, and is in no way intended to diagnose, endorese, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website. None of the content on PainRelief.com is warranted by the editors or owners of PainRelief.com or Eminent Domains Inc.
Thank you for visiting PainRelief.com
Senior Editor, Marie Benz MD.
For more information, or for advertising options please email: info@MedicalResearch.com or mariebenz@yahoo.com
